Former Green Bay Packers quarterback told FOX Business’ “KennedyMonday, he is an investor in the pharmaceutical company Prevacus, which is developing a concussion drug called Prevasol, which could be the first step in preventing CTE.
“Concussions are going to happen, no matter how good the helmets are,” Favre explained. “Spending more resources and time on prevention, rather than on a certain type of treatment, is where [the NFL is] missing.”
Prevacus President and Founder Dr Jacob Vanlandingham joined the conversation to explain how Prevasol works. He said the treatment should be used directly after a concussion to limit long-term damage.
The drug, taken via a nasal spray, is said to help repair nerves and promote cell growth, and has entered the first phase of human trials. Vanlandingham explained that Prevasol is considered to be a “neuro-steroid” which penetrates the blood-brain barrier “relatively quickly”.
“We can get the drug to the brain in less than five minutes,” he said. “And our plan is, when we get that diagnosis on the playing field, to give the drug through the nose, to get it quickly into the brain.”
Once the drug enters the nucleus of the brain, Vanlandingham added, it simultaneously reduces swelling, inflammation and oxidative stress. The doctor expects Phase 1 trials to end this year.
|ODYY||ODYSSÉE INTL GROUP INC||0.333||-0.07||-17.80%|
Prevacus was recently acquired by Odyssey Group International – publicly traded under ODYY – which allowed the company to conduct trials with financial freedom.